Post-marketing studies. The work of the drug safety research unit

Drug Safety

Volumn 19, Issue 5, 1998, Pages 343-353

  Mackay, Fiona Jean ^a  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COHORT ANALYSIS; DATA BASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; GENERAL PRACTICE; PRENATAL EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM;

ANTIPSYCHOTIC AGENTS; EPIDEMIOLOGIC METHODS; FEMALE; GOVERNMENT AGENCIES; GREAT BRITAIN; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; PRESCRIPTIONS, DRUG; PRODUCT SURVEILLANCE, POSTMARKETING; RISPERIDONE;

EID: 0031763899     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199819050-00002     Document Type: Editorial

References (37)

1. Rawson NSB, Pearce GL, Inman WHW. Prescription-event monitoring: methodology and recent progress. J Clin Epidemiol 1990; 43 (5): 509-22
2. Rawson NSB. Post-marketing surveillance. In: Hansch C, Sammes PG, Taylor JB, editors. Comprehensive medicinal chemistry. Vol. 1. General principles. Oxford: Pergamon Press, 1990: 625-55
3. Dunn NR, Thorogood M, De Caestecker L, et al. Myocardial infarction and oral contraceptives, a retrospective case control study in England and Scotland ('MICA' Study). Pharmacoepidemiol Drug Saf 1997; 6: 283-9
4. Joint Committee of ABPI, BMA, CSM and RCGP. Guidelines on post-marketing surveillance. BMJ 1988; 296: 399-400
5. Waller PC, Wood SM, Langman MJS, et al. Review of company postmarketing surveillance studies. BMJ 1992; 304: 1470-2
6. Rawlins MD, Jefferys DB. United Kingdom product licence applications involving new active substances. 1987-1989: their fate after appeals. Br J Clin Pharmacol 1991; 302: 223-5
7. Pringle M, Hobbs R. Large computer databases in general practice. Of little use unless high quality data are collected. BMJ 1991; 302: 741-2
8. Meyboom RHB, Egberts ACG, Edwards R, et al. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16 (6): 355-65
9. Waller PC, Coulson RA, Wood SM. Regulatory pharmacovigilance in the United Kingdom: current principles and practice. Pharmacoepidemiol Drug Saf 1996; 5: 363-75
10. Bem JL, Mann RD, Rawlins MD. Review of yellow cards 1986 and 1987. BMJ 1988; 296: 1319
11. Belton KJ, Lewis SC, Payne S, et al. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 1995; 39: 223-6
12. Carson JL, Strom BL, Maislin G. Screening for unknown effects of newly marketed drugs. In: Strom BL, editor. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley & Sons, 1994: 431-47
13. Freemantle SN, Pearce GL, Wilton LV, et al. The incidence of the most commonly reported events with 40 newly marketed drugs a study by prescription-event monitoring. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 1: S1-S62
14. Mann RD. Prescription-event monitoring: its role in ensuring new drug safety. Prescriber 1996; 7 (5): 102-4
15. Mann RD, Wilton LV, Pearce GL, et al. Prescription-event monitoring (PEM) in 1996 - a method of non-interventional observational cohort pharmacovigilance. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 3: S5-11
16. Mackay FJ, Wilton LV, Pearce GL, et al. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997; 38 (8): 881-6
17. Council for International Organisations of Medical Sciences in collaboration with the World Health Organization. International Ethical Guidelines for Biomedical Research involving human subjects: Geneva, 1993
18. Dunn N, Freemantle S, Pearce G, et al. Galactorrhoea with moclobemide [letter]. Lancet 1998; 351: 802
19. Mackay FJ, Dunn NR, Wilton LV, et al. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf 1997; 6: 235-46
20. Wilton L, Pearce G, Martin RM, et al. The outcome of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998; 105: 882-9
21. Turner S, Longworth A, Nunn AJ, et al. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ 1998; 316: 343-5
22. Mackay FJ, Wilton LV, Pearce GL, et al. The safety of risperidone: results of a post-marketing surveillance study on 7684 patients. Hum Psychopharmacol Clin Exp 1998; 13 (6); 413-8
23. Coulter DM. Reasons for stopping drugs are monitored in New Zealand. BMJ 1996; 313: 756
24. Coulter DM, Edwards IR, McQueen EG. Post-marketing surveillance in the general population: New Zealand. In: Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press, 1986: 119-34
25. McAvoy BR, Kaner EFS. General practice postal surveys: a questionnaire too far? BMJ 1996; 313: 732-3
26. Sinclair J, Birtwhistle J, Baldwin D. The tolerability of venlafaxine. Rev Contemp Pharmacother 1998; 9: 333-44
27. Mackay FJ, Wilton LV, Pearce GL, et al. United Kingdom experience with alendronate and oesophageal reactions. Br J Gen Pract 1998; 48: 1161-2
28. Stephens MBD, Wilton LV, Pearce GL, et al. Visual field defects in patients taking vigabatrin [abstract]. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 2: S18
29. 2 agonists. Thorax 1998; 53: 558-62
30. Pringle M, Ward P, Chilvers C. Assessment of the completeness and accuracy of computer medical records in four practices committed to recording data on computer. Br J Gen Pract 1995; 45: 537-41
31. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766-8
32. Jick H, Terris B, Derby L, et al. Further validation of information recorded on a general practitioner based computerised data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1: 347-9
33. Johnson N, Mant D, Jones L, et al. Use of computerised general practice data for population surveillance: comparative study of influenza data. BMJ 1991; 302: 763-5
34. Beardon PHG, McGilchrist MM, McKendrick AD, et al. Primary Non-compliance with prescribed medication in primary care. BMJ 1993; 307: 846-8
35. The general practice research database: information for researchers. London: Office for National Statistics on behalf of the GPRD Advisory Management Board, 1996
36. Kane JM. Newer antipsychotic drugs: a review of their pharmacology and therapeutic potential. Drugs 1993; 46: 585-93
37. MacDonald TM, McDevitt DG. The Tayside Medicines Monitoring Unit (MEMO). In: Strom BL, editors. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley & Sons, 1994: 245-355